FCγRIIB-specific antibodies and methods of use thereof

Details for Australian Patent Application No. 2005247301 (hide)

Owner Macrogenics, Inc.

Inventors Bonvini, Ezio; Tuaillon, Nadine; Veri, Maria Concetta; Rankin, Christopher; Koenig, Scott; Stavenhagen, Jeffrey

Agent Fisher Adams Kelly

Pub. Number AU-B-2005247301

PCT Pub. Number WO2005/115452

Priority 60/582,044 21.06.04 US; 60/654,713 18.02.05 US; 60/582,045 21.06.04 US; 60/562,804 16.04.04 US

Filing date 15 April 2005

Wipo publication date 8 December 2005

Acceptance publication date 18 August 2011

International Classifications

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 1/20 (2006.01) Micro-organisms, e.g. protozoa - Bacteria

C12N 15/00 (2006.01) Mutation or genetic engineering

C12Q 1/37 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving peptidase or proteinase

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/115452 Priority application(s): WO2005/115452

18 August 2011 Application Accepted

  Published as AU-B-2005247301

15 December 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005247303-Treatment of polychondritis and mononeuritis multiplex with anti-CD20 antibodies

2005247299-Enteric solid oral dosage form of bisphosphonate containing a chelating agent